Discontinued — last reported Q4 '25
Operating Expenses
(Profit) and loss sharing under collaboration agreements
Over 3 years (FY 2021 to FY 2025), (Profit) and loss sharing under collaboration agreements shows a downward trend with a -100.0% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ4 2025Feb 10, 2026
How to read this metric
Expenses represent payments to partners, while income (if netted) represents the benefit of shared development costs or commercial success.
Detailed definition
This metric captures the company's share of profits or losses paid to or received from collaboration partners under join...
Peer comparison
Standard in the biopharma industry where co-development and co-promotion agreements are frequent.
Metric ID:
operating_expenses_collaboration_loss_profit_sharing_expenseHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.25M | $9.25M | $9.25M | $1.77M | -$1.36M | -$549K | $1.05M | $2.9M | -$1.03M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| QoQ Change | — | +0.0% | +0.0% | -80.9% | -177.0% | +59.7% | +291.8% | +175.7% | -135.3% | +100.0% | — | — | — | — | — | — |
| YoY Change | — | — | — | -80.9% | — | — | -40.5% | — | +24.7% | +100.0% | -100.0% | -100.0% | +100.0% | — | — | — |
Range-$1.36M – $9.25M
CAGR-100.0%
Avg YoY Growth-13.8%
Median YoY Growth-40.5%
Product Breakdown
| Segment | Q1 '24 |
|---|---|
| Tafasitamab Product and Service | -$1M |
| Total | -$1.03M |
Business Segments
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | -$1.03M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total | -$1.03M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Reportable Segment was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
(Profit) and loss sharing under collaboration agreements at Other Companies
Frequently Asked Questions
- What is Incyte's (profit) and loss sharing under collaboration agreements?
- Incyte (INCY) reported (profit) and loss sharing under collaboration agreements of $0 in Q4 2025.
- What is the long-term trend for Incyte's (profit) and loss sharing under collaboration agreements?
- Over 3 years (2021 to 2025), Incyte's (profit) and loss sharing under collaboration agreements has grown at a -100.0% compound annual growth rate (CAGR), from $37.02M to $0.
- What does (profit) and loss sharing under collaboration agreements mean?
- The net financial impact of sharing profits or losses with business partners on specific drug programs.